Echo Therapeutics Granted U.S. Patent for Prelude® SkinPrep System

      Echo Therapeutics Granted U.S. Patent for Prelude® SkinPrep System

PR Newswire

PHILADELPHIA, March 12, 2013

PHILADELPHIA, March 12, 2013 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony^® CGM System as a
non-invasive, wireless, transdermal continuous glucose monitoring system,
today announced that the U.S. Patent and Trademark Office (USPTO) has issued
U.S. Patent No. 8,386,027, "Skin Permeation Device For Analyte Sensing or
Transdermal Drug Delivery," for the Prelude SkinPrep System, the skin
permeation component of the Symphony CGM System.

(Logo:http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

The patent, describing a device and method for preparing the skin in a
controlled, dermabrasive manner to allow for either analyte extraction or drug
delivery, was granted on February 26, 2013. The claims encompass the Prelude
device and its typical method of use. According to the USPTO's initial
calculation of patent term, this patent will expire in 2030. However, this
patent may be entitled to additional patent term due to delays by the USPTO,
and may expire at a later date.

"Building on our positive fundamentals, we are excited to be issued this
patent for a key component of our Symphony CGM System," said Patrick T.
Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "This
patent is critical to our intellectual property strategy for protecting our
position in non-invasive continuous glucose monitoring and transdermal drug
delivery markets worldwide. Furthermore, this U.S. patent issuance serves
again to strengthen Echo's already formidable intellectual property estate."

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive,
wireless, transdermal continuous glucose monitoring system. Our target is
patients who could benefit from glucose monitoring in the hospital setting,
including critical care. Significant opportunity also exists for patients
with diabetes to use Symphony in the outpatient setting. Echo is also
developing its needle-free skin preparation component of Symphony, the
Prelude^® SkinPrep System, as a platform technology to enhance drug delivery
of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Echo's ongoing
studies, including the safety and efficacy of Echo's Symphony CGM System, the
failure of future development and preliminary marketing efforts related to
Echo's Symphony CGM and Prelude SkinPrep Systems, Echo's ability to secure
additional commercial partnering arrangements, risks and uncertainties
relating to Echo's and its partners' ability to develop, market and sell
diagnostic and transdermal drug delivery products based on its skin permeation
platform technologies, including the Symphony CGM and Prelude SkinPrep
Systems, the availability of substantial additional equity or debt capital to
support its research, development and product commercialization activities,
and the success of its research, development, regulatory approval, marketing
and distribution plans and strategies, including those plans and strategies
related to its Symphony CGM and Prelude SkinPrep Systems. These and other
risks and uncertainties are identified and described in more detail in Echo's
filings with the Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the year ended December 31,
2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K.
Echo undertakes no obligation to publicly update or revise any forward-looking
statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104
colimpio@echotx.com

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.

Website: http://www.echotx.com
 
Press spacebar to pause and continue. Press esc to stop.